05-02-05

Certificate of Mailing (37 C.F.R. §1.10):

PC25144A Transmittal for Respone to Restriction Requirement for Appln. No. 10/621,983

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV 723989180 US) in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 29th day of April 2005.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Group Art Unit: 1623

Cleo J. Chivikas Connolly, et al.

Examiner: Paul V. Ward

Serial No.: 10/621,983

Confirmation No.: 2161

Filed: July 17, 2003

For: KINASE INHIBITORS

Mail Stop AMENDMENT Honorable Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

Response to Restriction Requirement 1.

7 Pages;

Postcard 2.

1 Postcard; and

3. Total Fee Due Deposit Account.

Respectfully submitted,

Date: April 29, 2005

Vince P. Lipta **Agent For Applicants** Registration No. 53,225

Agouron Pharmaceuticals, Inc./A Pfizer Company Patent Department 10777 Science Center Drive San Diego, California 92121

Phone: 858-622-7908 Fax: (858) 678-8233

Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV 723989180 US) in an envelope addressed to: Mail Stop AMENDMENT, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 29th day of April 2005.

andria, VA 22313-1450 on this 29th day of April 2005. Christina M/Compelube

ĴŒV7239&91aous)

PE VOJO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Cleo J. Chivikas Connolly, et al.

Serial No.: 10/621,983

Confirmation No.: 2161

Filed: July 17, 2003

For: KINASE INHIBITORS

Group Art Unit: 1623

Examiner: Paul V. Ward

Mail Stop AMENDMENT Honorable Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Restriction Requirement mailed March 29, 2005 please reconsider the application based on the following:

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks begin on page 7 of this paper.